• About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
    • Publications
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • OncoFAP Radio Conjugates (Imaging)
    • OncoFAP Radio Conjugates (Therapy)
    • OncoFAP-GlyPro-MMAE
    • OncoACP3 (Imaging)
    • OncoACP3 (Therapy)
    • OncoCAIX
  • Press Releases & Media
    • Press Releases
    • Events
    • Media Library
    • Philogen in the news
  • Work with us
    • Careers
    • Partnering
  • Investors
    • Investor Relations
    • Shareholding
    • IPO
    • Press Releases
    • Financial Statements
    • Financial Calendar
    • Internal Dealing
    • Buyback
    • Analyst Coverage
    • Webinars
    • IR Contacts
  • Governance
    • Board of Directors
    • Board of Statutory Auditors
    • Documents & Procedures
    • Shareholders’ Meetings
    • Codice etico e Modello 231
    • Sustainability (ESG)
Governance
Investors
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
    • Publications
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • OncoFAP Radio Conjugates (Imaging)
    • OncoFAP Radio Conjugates (Therapy)
    • OncoFAP-GlyPro-MMAE
    • OncoACP3 (Imaging)
    • OncoACP3 (Therapy)
    • OncoCAIX
  • Press Releases & Media
    • Press Releases
    • Events
    • Philogen in the news
    • Media Library
  • Work with us
    • Careers
    • Partnering

News & Events

Investors, Press Releases

The Board of Directors approves the draft financial statements

Apr 27, 2021

The Board of Directors approves the draft financial statements and the consolidated financial statements as of 31 december 2020 (Courtesy English Translation) (Price Sensitive)

Last News & Events

May 2025 26

Deposito del Verbale dell’Assemblea degli Azionisti

May 2025 6

Il Consiglio di Amministrazione approva la Posizione Finanziaria Netta relativa al Primo Trimestre 2025

  • « Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 132
  • Next »

Privacy Policy / Cookie Policy

  Contacts

  • Follow
  • Follow

Philogen S.p.A. ©  Piazza La Lizza, 7 | 53100 Siena (SI) – ITALY | Nr. REA: SI-98772 | P.IVA e CF 00893990523 | Cap. Soc. € 5.731.226,64 i.v. | PEC: AFC@pec.philogengroup.it